Long-term management of depression: Tips for adjusting the treatment plan as the patient's needs change

Journal of Clinical Psychiatry

Volumn 70, Issue SUPPL. 6, 2009, Pages 32-37

  Shelton, Richard C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; LITHIUM CARBONATE; PAROXETINE; PLACEBO; VENLAFAXINE;

ARTICLE; BEHAVIOR THERAPY; CHRONICITY; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; DRUG EFFICACY; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; RECURRENT DISEASE; RELAPSE; REMISSION; RISK FACTOR; SLEEP DISORDER; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; BEHAVIOR THERAPY; CHRONIC DISEASE; CLINICAL PROTOCOLS; COGNITIVE THERAPY; COMORBIDITY; DEPRESSIVE DISORDER; DISEASE MANAGEMENT; HUMANS; LIFE CHANGE EVENTS; LONG-TERM CARE; PSYCHOTHERAPY; RECURRENCE; TREATMENT OUTCOME;

EID: 72549089788     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.8133su1c.05     Document Type: Article

References (23)

1. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry. 1997;54(11):989-991. PubMed
2. National Alliance on Mental Illness. Major depression. 2006. www.nami.org/Template.cfm?Section=By-Illness&Template=/TaggedPage/ TaggedPageDisplay.cfm&TPLID=54&ContentID=23039&lstid=326. Accessed April 22, 2009.
3. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. PubMed doi:10.1001/jama.289.23.3095 (Pubitemid 37432885)
4. STAR*D: Sequenced Treatment Alternatives to Relieve Depression. www.edc.pitt.edu/stard/. Accessed April 30, 2009.
5. Rush AJ, Trivedi JH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PubMed doi:10.1176/appi.ajp.163.11.1905
6. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225. PubMed
7. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171- 1180. PubMed doi:10.1017/S0033291700033146
8. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163(9):1542-1548. PubMed doi:10.1176/appi.ajp.163.9.1542
9. Kaymaz N, van Os J, Loonen AJ, et al. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2008;69(9):1423-1436. PubMed
10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. PubMed doi:10.1176/appi.ajp.163.1.28
11. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians. 1999;111(1):22-34. PubMed doi:10.1046/j.1525-1381.1999.09423.x
12. Harkness KL, Monroe SM. Severe melancholic depression is more vulnerable than non-melancholic depression to minor precipitating life events. J Affect Disord. 2006;91(2-3):257-263. PubMed doi:10.1016/j.jad.2005.12.009
13. Fournier JC, DeRubeis RJ, Shelton RC, et al. Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder. Br J Psychiatry. 2008;192(2):124-129. PubMed doi:10.1192/bjp.bp.107. 037234
14. Melartin TK, Rytsälä HJ, Leskelä US, et al. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J Clin Psychiatry. 2004;65(6):810-819. PubMed
15. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409-416. PubMed doi:10.1001/archpsyc.62.4.409
16. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):417-422. PubMed doi:10.1001/archpsyc.62.4.417
17. Dobson KS, Hollon SD, Dimidjian S, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol. 2008;76(3):468-477. PubMed doi:10.1037/0022-006X.76.3.468 (Pubitemid 351822347)
18. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci. 2008;9(10):788-796. PubMed doi:10.1038/nrn2345
19. Hollon SD, DeRubeis RJ, Evans MD. Causal mediation of change in treatment for depression: discriminating between nonspecificity and noncausality. Psychol Bull. 1987;102(1):139-149. PubMed doi:10.1037/0033-2909.102.1.139
20. Inoue T, Li XB, Abekawa T, et al. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur J Pharmacol. 2004;497(3):311-316. PubMed doi:10.1016/j.ejphar.2004.06.061 (Pubitemid 39164896)
21. Sheline YI, Barch DM, Donnelly JM, et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an FMRI study. Biol Psychiatry. 2001;50(9):651-658. PubMed doi:10.1016/S0006-3223(01)01263-X
22. DeRubeis RJ, Evans MD, Hollon SD, et al. How does cognitive therapy work? cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression. J Consult Clin Psychol. 1990;58(6):862-869. PubMed doi:10.1037/0022-006X.58.6.862
23. Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry. 2007;164(5):778-788. PubMed doi:10.1176/appi.ajp.164.5.778